Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings: Misses Revenue Forecasts, Posts Wider Net Loss

GuruFocus Research

10 May 2024 at 1:55 pm·3-min read

Revenue: Reported $69.2 million for Q1 2024, a significant increase from $31.6 million in Q1 2023, but fell short of the estimated $75.41 million.
Net Loss: Narrowed to $25.279 million in Q1 2024 from $30.130 million in Q1 2023, exceeding the estimated loss of $21.95 million.
Earnings Per Share (EPS): Recorded at -$0.54, underperforming against the estimated -$0.44.
Product Sales: Showed robust growth with $68.9 million in Q1 2024, a 137% increase year-over-year, driven by strong demand for LIVMARLI.
Cash Position: Ended the quarter with $302.8 million in cash and cash equivalents, up from $286.3 million at the end of the previous quarter.
Operating Expenses: Rose to $95.7 million in Q1 2024 from $58.7 million in Q1 2023, reflecting increased investment in research and development and sales activities.
Regulatory Milestones: Achieved FDA approval for LIVMARLI for cholestatic pruritus in PFIC patients, supporting long-term growth prospects.

Warning! GuruFocus has detected 2 Warning Signs with MIRM.

Mirum Pharmaceuticals Inc (NASDAQ:MIRM) disclosed its first quarter financial results for 2024, revealing a mixed performance with revenue falling short of analyst expectations and a widened net loss. The company released its 8-K filing on May 8, 2024, providing insights into its financial health and operational progress.

Company Overview

Mirum Pharmaceuticals Inc, a biopharmaceutical entity, focuses on developing novel therapies for rare and orphan diseases. Its flagship product, Livmarli, an ileal bile acid transporter inhibitor, is approved for treating cholestatic pruritus in Alagille syndrome patients. The company is also advancing Maralixibat for pediatric conditions and Volixibat for adult cholestatic liver diseases.

Financial Performance Analysis

For Q1 2024, Mirum reported total revenue of $69.2 million, a significant increase from $31.6 million in Q1 2023 but below the analyst estimate of $75.41 million. This revenue includes $68.9 million from global product sales, marking a 137% increase year-over-year, driven by strong demand for Livmarli. However, the company's operating expenses surged to $95.7 million from $58.7 million in the previous year, reflecting higher costs in research and development, and selling, general, and administrative expenses.

The net loss for the quarter deepened to $25.28 million, or $0.54 per share, compared to a net loss of $30.13 million, or $0.80 per share, in the same period last year. This loss was more substantial than the anticipated $21.95 million, underscoring increased operational costs and investment in research activities.

Strategic Developments and Regulatory Milestones

Mirum achieved significant regulatory milestones, including the FDA's approval of Livmarli for treating cholestatic pruritus in PFIC patients. The company also remains on track with its New Drug Application submission for Chenodal in CTX, expected in the first half of 2024. Furthermore, interim analyses for Volixibat in the VISTAS and VANTAGE studies are scheduled for June 2024, which could potentially enhance Mirum's portfolio in cholestatic diseases.

Financial Position and Outlook

As of March 31, 2024, Mirum's cash and cash equivalents stood at $302.8 million, an increase from $286.3 million at the end of 2023, providing the company with a robust financial base to support ongoing and future clinical programs. Mirum reiterated its full-year revenue guidance of $310 to $320 million, reflecting confidence in its commercial strategies and product demand.

Conclusion

Despite the revenue shortfall and increased net loss in Q1 2024, Mirum Pharmaceuticals Inc continues to demonstrate strong commercial execution and progress in its clinical development pipeline. The company's strategic initiatives, particularly in expanding indications for its approved products and advancing its clinical studies, are expected to drive long-term growth and enhance its position in the biopharmaceutical sector focused on rare diseases.

Investors and stakeholders will likely keep a close watch on the upcoming interim study results and regulatory developments, which could be pivotal in shaping the company's trajectory in the coming months.

For detailed financial figures and further information, refer to Mirum Pharmaceuticals Inc's 8-K filing.

Explore the complete 8-K earnings release (here) from Mirum Pharmaceuticals Inc for further details.

This article first appeared on GuruFocus.

Simply Wall St.
Shareholders in Suntec Real Estate Investment Trust (SGX:T82U) are in the red if they invested five years ago
For many, the main point of investing is to generate higher returns than the overall market. But the main game is to...
The Edge Singapore
Singtel's FY2024 earnings down 64% y-o-y to $795 mil, boosts full year dividend to 15 cents; announces new growth plan
Singtel is increasing dividend for the third year
Simply Wall St.
3 High Yield Dividend Stocks On SGX With Yields Up To 8.2%
As Singapore continues to embrace technological advancements, the recent unveiling of a Web3 digital banking platform by Alchemy Pay highlights the market's progressive adaptation to the evolving landscape of digital finance. In this dynamic environment, high-yield dividend stocks on the SGX offer investors potential stability and consistent returns, qualities that are particularly appealing amid the rapid changes in financial technology and payment systems.
CNN Business
Nvidia’s incredibly pricey shares are about to get much cheaper
Nvidia announced a 10-for-1 stock split on Wednesday, making buying shares in the red-hot semiconductor company more accessible for individual investors.
AFP News
Nvidia profits soar on demand for AI power
Nvidia said Wednesday its quarterly net profit rocketed by seven times year-on-year on demand for its chips to power artificial intelligence in data centers.The California-based company reported a net profit of $14.9 billion, while its revenue of $26 billion was almost four times what it took in during the same fiscal quarter last year.
The Independent
Trump Media stock slumps after reporting $327.6m first quarter loss, costing former president more than $766m
Company says losses are result of recent merger but share price has dropped 13.2% since Friday
GOBankingRates
If You Invested $20,000 in These Companies 20 Years Ago, You Would Be a Millionaire Now
Making a million dollars is no easy task if you're starting from scratch. It's going to take some combination of time, luck and work. Sometimes, though, if you're starting with some money, you can let...
Barrons.com
Nvidia Stock Rises as Earnings Beat High Expectations
Nvidia fulfilled the world’s high expectations with its April quarter results. “The next industrial revolution has begun,” CEO Jensen Huang said in the Wednesday earnings release. “Companies and countries are partnering with Nvidia to shift the trillion-dollar traditional data centers to accelerated computing and build a new type of data center—AI factories—to produce a new commodity: artificial intelligence.”
The Independent
Michigan man who had seizure on Royal Caribbean cruise forced to pay $2500 bill before evacuating
Vincent Wasney returned home from cruise in thousands of dollars of medical debt
The Smart Investor
Forget the S&P 500 ETF: These 3 US Stocks Gave Better Returns
Over the past five years, there were three US stocks that beat the 93% return of the SPDR S&P 500 ETF (NYSE: SPY). And no, they are not any of the Magnificent 7 stocks. The post Forget the S&P 500 ETF: These 3 US Stocks Gave Better Returns appeared first on The Smart Investor.
Reuters
Canada's Power Corp shuts down China unit, lays off staff, sources say
Power Corporation of Canada (Power Corp) has shut its China investment unit and dismissed all staff, said two people briefed on the matter, becoming the latest Western financial firm to pull back amid the country's economic challenges. Power Sustainable, which is the asset management arm of Power Corp and manages $4.5 billion of assets globally, started laying off all of its 17 local staff in recent weeks as it moved towards shutting down the Shanghai-based unit, said the people. Economic slowdown has seen many of the Western financial firms that scrambled to expand China operations a few years ago take a hit on their earnings and rein in their ambitions for what was a key piece of their global growth strategy.
Thomson Reuters StreetEvents
Q2 2024 Analog Devices Inc Earnings Call
Q2 2024 Analog Devices Inc Earnings Call
Reuters
Analysis-Bulls beat a path to China stock shop but foreigners dare not go in
Emboldened by China's latest measures and pledges to fix the weakest parts of its struggling economy, domestic investors are scooping up shares in a cheap stock market, while most foreign investors are hopeful but taking it slow. Last week's sweeping measures to support the property sector, which authorities dubbed as historic, were the latest in a series of steps China has taken since February in a bid to boost consumption, funnel state money into priority sectors and underpin the stock market. "To some extent, I think what's been announced isn't yet of a scale that is going to start putting a meaningful kind of tens of percentage points onto GDP," said Sunil Krishnan, head of multi-asset funds at Aviva Investors in London.
Reuters
Fed shifts talk to 'scenarios' as policy grows less certain
Federal Reserve Chair Jerome Powell said in a May 1 press conference he didn't want to talk about economic "hypotheticals," but that's what he and other U.S. central bank officials have shifted towards in discussing monetary policy that has hit an uncertain juncture in the effort to tame inflation. Dropping what had been explicit guidance about the likelihood of interest rate cuts this year, Powell and other Fed officials are instead focusing attention on broadly different near-term paths the economy might follow, and their likely reaction to each case. Former Fed officials and staffers with experience attending meetings of the policy-setting Federal Open Market Committee say that's a sign of just how uncertain policymakers feel right now and is meant to shift attention from the detailed economic and policy projections they produce each quarter and onto a wider array of potential outcomes.
AFP News
US Fed's rate meeting minutes show growing inflation concerns
A strong US economy and an uptick in inflation led the Federal Reserve's rate-setting committee to conclude that progress against rising prices had stalled, according to minutes of its most recent meeting published Wednesday.The minutes of the two-day Federal Open Market Committee (FOMC) meeting show that policymakers generally felt that "recent data had not increased their confidence that inflation was moving sustainably toward two percent."
Insider Monkey
Billionaire Ray Dalio is Selling These Tech Stocks in 2024
When billionaire Ray Dalio left his empire Bridgewater Associates in 2022, the inflation storm and economic uncertainties were pummeling the financial markets. While the fund had started 2022 on a positive note, its returns came crashing down it the last quarter of the year. According to a Bloomberg report, The Pure Alpha fund of Bridgewater […]
Yahoo Finance
US federal budget crosses grim milestone as interest payments overtake defense spending
Interest payments on the national debt are set to eclipse defense spending this year for the first time ever.
Barrons.com
Tesla Stock Is Up Because the EV News From China Isn’t Always Bad
The stock rebounded from a Monday loss sparked by disappointing results from Li Auto. XPeng’s earnings were surprisingly strong.
Simply Wall St.
Sea Limited's (NYSE:SE) one-year returns climbed after last week's 13% gain, institutional investors must be happy
Key Insights Given the large stake in the stock by institutions, Sea's stock price might be vulnerable to their trading...
Reuters
Gold prices dip after record highs on profit taking, rate cut bets cool
Gold prices dipped over 1% on Wednesday as the gold rally cooled with investors booking profits, as traders pulled back from bets on Federal Reserve's rate cuts this year. Spot gold fell 1.8% to $2,377.43 per ounce by 1858 GMT. "You're seeing some week-long liquidation, some profit taking by the shorter term futures traders; all of which is not unusual in a market that hit a record high," said Jim Wyckoff, senior analyst at Kitco Metals.

Straits Times Index

S&P 500

Dow

Nasdaq

Bitcoin USD

CMC Crypto 200

FTSE 100

Gold

Crude Oil

10-Yr Bond

Nikkei

Hang Seng

FTSE Bursa Malaysia

Jakarta Composite Index

PSE Index

Company Overview

Financial Performance Analysis

Strategic Developments and Regulatory Milestones

Financial Position and Outlook

Conclusion

Latest stories